Industry News
Pembrolizumab treatment causes immune cells in blood to gain characteristics of reinvigoration
9/17/2015
Treating patients with metastatic melanoma with the immunotherapy drug pembrolizumab (Keytruda) caused immune cells called CD8-positive (CD8+) T cells in the patient's blood to express markers of...
Frequency of certain immune cells in blood may predict metastaticmelanoma response to pembrolizumab
9/17/2015
Among patients with metastatic melanoma treated with the immunotherapy drug pembrolizumab (Keytruda), those whose cancer responded to the treatment had a higher frequency of immune cells called T...
CAR T-cell therapy trial yields early promise for lymphoma andleukemia patients
9/17/2015
In a phase I/IIa trial, third-generation CD19 CAR T-cell therapy combined withchemotherapy pretreatment resulted in complete response in some lymphoma and leukemiapatients, according to data...
Multiple myeloma patients vulnerable to 'financial toxicity,' due to costly treatments
9/17/2015
Even patients with health insurance who have multiple myeloma may be vulnerable to "financial toxicity" - including those who make over $100,000 a year - because of the higher use of novel...
New method of immunotherapy delivery lowers pain in children withhigh-risk neuroblastoma
9/17/2015
In children with high-risk relapsed/refractory neuroblastoma, long-term infusion (LTI) of the antibody ch14.
Small protein engineered to target PD-L1 is more potent than anti-PD-L1antibody immunotherapeutic
9/17/2015
An engineered high-affinity PD-1 small protein that can bind to PD-L1 on tumors was found to be a more effective anticancer immunotherapeutic than conventional antiPD-L1 antibodies, and this small...
Microbiome implicated in sickle cell disease - but antibiotics can counter its effects
9/17/2015
New research on sickle cell disease (SCD) has found that using antibiotics to deplete the body's microbiome may prevent acute sickle cell crisis and could offer the first effective strategy for...
New catalyst yields more accurate PSA test
9/17/2015
Say you've been diagnosed with prostate cancer, the second-leading cause of cancer death in men. You opt for surgery to remove your prostate.
Immune system-boosting agent CpG-B reduced early-stage melanoma recurrences
9/17/2015
Among patients with clinically stage 1 or stage 2 melanoma, those treated withthe immune system-boosting agent CpG-B were less likely to experience recurrence of theirdisease than those who...
Penn team pinpoints immune changes in blood of melanoma patients on PD-1 drugs
9/17/2015
A simple blood test can detect early markers of "reinvigorated" T cells and track immune responses in metastatic melanoma patients after initial treatment with the anti-PD-1 drug pembrolizumab...